

Clinical trial simulation: Planning with the OCTAVE framework and some computational principles

Kim May Lee

Department of Biostatistics and Health Informatics

King's College London, UK

16th April 2026

HRB-TMRN webinar

Outline of the talk

- Idea of clinical trial simulation (CST)
- OCTAVE framework for planning CTS
- The use of pseudocode
- Data generation approaches
- Validation of code
- Approximation approaches
- Graphical presentation and tools

Other topics covered in the tutorial paper



TUTORIAL IN BIostatISTICS | [Open Access](#) | CC BY


Clinical Trial Simulation: Planning With the OCTAVE Framework, Implementation and Validation Principles

[Kim May Lee](#) , [Babak Choodari-Oskooei](#), [Michael J. Grayling](#), [Peter Jacko](#), [Peter K. Kimani](#), [Aritra Mukherjee](#), [Philip Pallmann](#), [Tom Parke](#), [David S. Robertson](#), [Ziyan Wang](#), [Christina Yap](#), [Thomas Jaki](#) ... [See fewer authors](#) ^

First published: 16 March 2026 | <https://doi.org/10.1002/sim.70449> | [VIEW METRICS](#)

- Components of clinical trials
- Simulation tasks management
- Presenting CTS result to stakeholders
- Reporting CTS in a grant application
- Suggestions on making code open-access


What is simulation



A simulation study uses a computer program to learn about different situations to understand what might happen, instead of doing a real-world experiment¹


¹ Sacks, J., Welch, W.J., Mitchell, T.J. and Wynn, H.P., 1989.
Design and analysis of computer experiments. *Statistical science*, 4(4), pp.409-423.

What is simulation



A simulation study uses a computer program to learn about different situations to understand what might happen, instead of doing a real-world experiment¹


Clinical trial simulation uses computer models to explore trial scenarios and outcomes without running the real trial



¹ Sacks, J., Welch, W.J., Mitchell, T.J. and Wynn, H.P., 1989. Design and analysis of computer experiments. *Statistical science*, 4(4), pp.409-423.


Clinical trial simulation can...

- Offer a preview of trial procedures and results before real-world implementation



Clinical trial simulation can...

- Offer a preview of trial procedures and results before real-world implementation




Clinical trial simulation can...

- Evaluate the properties of a design and analysis strategy by repeated sampling




Summarise outputs over m replications
e.g. $P(\text{reject } H_0)$, bias of estimated effect




Clinical trial simulation can...


- Identify the optimal design set-up when the whole process is repeated with different data generating mechanisms



Summarise outputs over m replications
e.g. $P(\text{reject } H_0)$, bias of estimated effect



Repeat this m times



Complex innovative clinical trial designs


Trial set-up with unconventional design features, where closed-form mathematical expressions for

- sample size calculation
 - unbiased effect size estimation
- are **unavailable**

Complex innovative clinical trial designs


Trial set-up with unconventional design features, where closed-form mathematical expressions for

- sample size calculation
 - unbiased effect size estimation
- are **unavailable**




E.g., set-up consisting

- Rules that guide trial activities



- Complex rules for statistical decision making

- Multiple interventions and subpopulations



The **OCTAVE** framework



Objectives of conducting CTS



Characteristics of underlying factors



Trial set-up



Analysis methods



Valuation

Characteristics of design ←

→ Performance of analysis method



Evidence

← Reporting

→ Reproducibility


The OCTAVE framework



Objectives of conducting CTS



Characteristics of underlying factors



Trial set-up



Analysis methods



Valuation



Evidence

Define structure of data generating mechanism

Characteristics of design


Performance of analysis method

Reporting

Reproducibility




Objectives of conducting CTS





Objectives of conducting CTS- example 1




Assess the sensitivity of **one design** and **analysis** strategy with respect to some underlying **assumptions**

**Evaluate the properties of a four-arm, two-stage design with a sequential t-test assuming different delay lengths in the endpoint*



Objectives of conducting CTS- example 2



Compare the properties of **multiple designs** that use the **same analysis methods** under a given set of **assumptions**

Investigate the performance of different **randomization approaches in a platform trial with **beta-binomial outcome model***

Underlying factors

- Related to **trial design** and/or **conduct**
- The *true* properties or characteristics are unknown to the investigators at the planning stage
- The properties or characteristics cannot be altered by human intervention.

Underlying factors

- Related to **trial design** and/or **conduct**
- The *true* properties or characteristics are unknown to the investigators at the planning stage
- The properties or characteristics cannot be altered by human intervention.


Examples: treatment effect of endpoint(s), variability in how participants respond to a treatment, prognostic covariates, disease progression, missing data types

Underlying factors

- Related to trial design and/or conduct
- The *true* properties or characteristics are unknown to investigators at the planning stage
- The properties or characteristics cannot be controlled by the intervention.

We can select the factors but we hardly know the true numerical representations

Examples: treatment effect of endpoint(s), variability in how participants respond to a treatment, prognostic covariates, disease progression, missing data types



Characteristics of underlying factors

Assumptions





Trial set-up

- A trial design is a structured plan that describes how a study will be conducted to address clinical research questions.
- We refer to trial set-up as the **statistical and numerical aspects** of the plan



Trial set-up


- A trial design is a structured plan that describes how a study will be conducted to address clinical research questions.
- We refer to trial set-up as the **statistical and numerical aspects** of the plan

Examples of trial set-up: number of interventions, randomization method, sample size per arm/per stage, number of interim analyses, rules for guiding trial activities and statistical decisions

Interim analysis





OR



Recalculate n at interim analysis









A **test case** comprises

- the underlying factors,
- the trial set-up, and
- specification of analysis model/ methods


each set to concrete **numerical inputs** for this scenario



- A **test case** can be used to evaluate the replicated outputs *conditionally* given the *specified ancillary configuration*—without averaging across alternative configurations.






- Statistical techniques and procedures used to evaluate accumulating trial data.
- They rely on *underlying assumptions* regarding the data or the data generating process.





Examples:

- Hypothesis rejection rate
- Expected sample size
- Bias of estimators
- Expected trial duration





Report Monte Carlo simulation errors to capture the variability in the point estimates of measures



Select the relevant ones, may split into primary and secondary metrics

Operating characteristics & performance measures

Example:

Is a particular Bayesian design worth implementing?

Primary metrics:

- i) Predictive probability of success
- ii) Expected sample size

Secondary metrics:

- i) Frequentist type I error rate
- ii) Mean squared error of estimated treatment effects

Select the relevant ones,
may split into primary
and secondary metrics

Operating characteristics &
performance measures

Valuation of complex designs

Statistical
benefits



Implementation
complexity

- **Operational complexity**

- E.g., the average time to execute interim analyses, staff hours required per participant

- **Regulatory uncertainty**

- E.g., additional months to approval compared with conventional designs

- **Lack of familiarity with novel designs**

- E.g., the number of staff training sessions needed before trial launch

Objective of conducting CTS



Characteristics of underlying factors



Trial set-up



Analysis methods



Valuation: properties of design and analysis



Evidence: reporting & reproducibility

Numerical input defines a test case

Data generating mechanism

Replicate m times

Simulated dataset 1

Simulated dataset 2

...

Simulated dataset m

Data analysis output 1

Data analysis output 2

...

Data analysis output m

Summarise outputs over m replications

Operating Characteristics & performance measures

Select the relevant ones

Objective of conducting CTS

Numerical

Data generating mechanism

Clear documentation

- should explicitly state which components vary
- facilitates reproduction of the simulation results
- showing the output of single runs and repeated runs
 - confirms inclusion of the required analyses and summaries
 - help start the discussion and clarify what is happening

Evidence: reporting & reproducibility

relevant ones

performance measures

O

C

T

A

V

E

Pseudocode for outlining simulation details

- Break the simulation process down into specific steps and decision-making algorithms
- Show the overall coding structure and flow

Identify logical flaws or missing decision points before coding



Algorithm 1 Pseudocode for the two-endpoint Bayesian two-stage design

```
for  $j \in (1 : M_{\text{sim}})$  do
   $i \leftarrow j$ 
  Simulate accrual, outcomes and drop-out indicator for  $N_{\text{max}}$  subjects.
   $D_{\text{interim}} \leftarrow$  observed outcomes of  $N_{\text{interim}}$ 
  # — Interim analysis stage —
   $PP_A \leftarrow P(\hat{\mu}_{\text{treat},A} > \hat{\mu}_{\text{control},A} \mid D_{\text{interim}})$ 
   $PP_B \leftarrow P(\hat{\mu}_{\text{treat},B} > \hat{\mu}_{\text{control},B} \mid D_{\text{interim}})$ 
  if  $PP_A > \theta_{\text{eff}}$  and  $PP_B > \theta_{\text{eff}}$  then
    Stop early  $\leftarrow$  Efficacy
    Trial continues  $\leftarrow$  FALSE
     $PP_{\text{primary}} \leftarrow PP_A$ 
    if  $PP_{\text{primary}} > \theta_{\text{final}}$  then
      Trial outcome  $\leftarrow$  Success
    else
      Trial outcome  $\leftarrow$  Failure
    end if
     $i \leftarrow j + 1$ 
  else if  $PP_A < \theta_{\text{fut}}$  or  $PP_B < \theta_{\text{fut}}$  then
    Stop early  $\leftarrow$  Futility
    Trial continues  $\leftarrow$  FALSE
     $i \leftarrow j + 1$ 
  else
    Stop early  $\leftarrow$  No
    Trial continues  $\leftarrow$  True
  end if
  # — Final analysis stage (if trial continues) —
  if Trial continues is TRUE then
     $D_{\text{final}} \leftarrow$  Observed outcomes of  $N_{\text{max}}$ 
     $PP_{\text{primary}} \leftarrow P(\hat{\mu}_{\text{treat},A} > \hat{\mu}_{\text{control},A} \mid D_{\text{final}})$ 
    if  $PP_{\text{primary}} > \theta_{\text{final}}$  then
      Trial outcome  $\leftarrow$  Success
    else
      Trial outcome  $\leftarrow$  Failure
    end if
  end if
   $i \leftarrow j + 1$ 
end for
Calculate and return probability of success using Trial Outcome
```

Data generation approaches

Individual participant level



- Created dynamically or as a database in advance



Data generation approaches

Individual participant level

- Created dynamically or as a database in advance
- Add complexity to code & computing storage
- Captures underlying correlation structures inherently



Data generation approaches




Individual participant level

- Created dynamically or as a database in advance
- Add complexity to code & computing storage
- Captures underlying correlation structures inherently

VS

Aggregated level

- Explicit assumptions on data
- Less complex code, quicker to run & less storage
- Cannot explore aspects related to individual participants



Validation of code/algorithm


- **Unit testing** to ensure each part functions correctly
 - E.g. test randomization & stopping rules in isolation
- Include **checks** that stop the code and provide informative **error** messages
- **Statistical analysis validation**
 - Existing methods: Compare to trusted software or known results
 - New methods: Hand-check results on small datasets or compare with similar approaches.
- Test **extreme cases** to assess the **robustness** of the algorithm to variations in input parameters

Validation of code/algorithm (cont.)

- Inspection of **simulated data**, e.g., check
 - simulated data reflect the intended treatment effects and trial parameters
 - interim analysis datasets are correctly extracted
 - trial progression reflects interim decisions

- **Integration testing**


E.g., individual participant data generation → randomization → outcome generation → analysis according to decision rules



For computation of performance measures

Approximation approaches

Useful when computing resources are limited



- Gaussian process and optimization approaches
 - **ROSA approach**¹: choose an optimal set of test cases for sensitivity analysis with respect to the underlying assumptions
 - **adaptr R package**²: compute Bayesian multi-arm multi-stage designs with early stopping
- *Linear interpolation*
 - **gsbDesign R package**³: approximate operating characteristics of group-sequential Bayesian designs over a range of true treatment effects

¹Han et al. *The American Statistician*. 2024;78(1):76-87.

²Granholt et al. *Journal of Open Source Software*. 2022;7(72):4284.

³Gerber et al. *Journal of Statistical Software*. 2016;69:1-23.

Graphical presentation and tools

- 2D plots
 - **x-axis**: varying components of CTS, **y-axis**: performance measures
 - **Line curves** connecting **discrete points** should be used cautiously
 - **Truncation of the y-axis** range may be employed to clarify trends, with all truncated values **explicitly reported** in the figure caption
 - Include **confidence intervals** computed using the **Monte Carlo errors**

Graphical presentation and tools

- 2D plots
 - **x-axis**: varying components of CTS, **y-axis**: performance measures
 - **Line curves** connecting **discrete points** should be used cautiously
 - **Truncation of the y-axis** range may be employed to clarify trends, with all truncated values **explicitly reported** in the figure caption
 - Include **confidence intervals** computed using the **Monte Carlo errors**
- Modern tools for automated visualizations e.g. **AIRSHIP¹**, **INTEREST²**, **simsum³**, and **rsimsum⁴** enable results to be displayed in a multi-dimensional view for identification of unique results (if there are any)

¹Meyer et al. *SoftwareX*. 2023;22:101347

²Gasparini et al. *Journal of data science, statistics, and visualisation*. 2021;1(4).

³White. *The Stata Journal*. 2010;10(3):369-85.

⁴Gasparini. *Journal of Open Source Software*. 2018;3(26):739.

Thank you

- Kim May Lee
- kim.lee@kcl.ac.uk
- **Department of Biostatistics and Health Informatics, King's College London, UK**

Statistics
in Medicine



TUTORIAL IN BIOSTATISTICS | Open Access |

Clinical Trial Simulation: Planning With the OCTAVE Framework, Implementation and Validation Principles

[Kim May Lee](#) [Babak Choodari-Oskooei](#), [Michael J. Grayling](#), [Peter Jacko](#), [Peter K. Kimani](#), [Aritra Mukherjee](#), [Philip Pallmann](#), [Tom Parke](#), [David S. Robertson](#), [Ziyan Wang](#), [Christina Yap](#), [Thomas Jaki](#) ... [See fewer authors](#) ^

First published: 16 March 2026 | <https://doi.org/10.1002/sim.70449> |

VIEW METRICS